Sunday, September 24, 2023
Psoriatic Arthritis Learning Center:
Psoriatic arthritis (PsA) is a chronic, progressive systemic inflammatory disorder that may result in permanent joint damage and disability. Patients with PsA have highly heterogeneous disease courses and health consequences beyond joint function, such as cardiovascular disease. Of the 125 million people worldwide with psoriasis, between 10% and 30% will also develop PsA. In addition to physical health effects, PsA greatly impacts quality of life, with approximately 40% of people reporting their disease to be a large problem in everyday life. This page provides education on the latest therapeutic strategies for appropriate PsA management.
Supported by an educational grant from
Lilly
For further information concerning Lilly grant funding visit
www.lillygrantoffice.com
Review the pathophysiology and latest treatments for psoriatic arthritis.
Download
Chair
Clinical Professor
University of Washington School of Medicine
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Seattle, Washington, United States
Member
Professor of Medicine
Oregon Health & Science University
Portland, Oregon, United States
Member
Professor of Medicine
University of Toronto
Senior Scientist
Krembil Research Institute
University Health Network
Toronto, Ontario, Canada
Member
Clinical Professor of Dermatology and
Medical Director
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Member
Nurse Practitioner
Department of Allergy, Immunology and Rheumatology
University of Rochester Medical Center
Rochester, New York, United States
Member
Professor of Medicine
UC San Diego Health
La Jolla, California, United States
Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Galapagos; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma, Inc.
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Gilead Sciences, Inc.; Galapagos; Eli Lilly and Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma, Inc.
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Allergan, Inc.; Avotres Therapeutics; Beiersdorf; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Dermira Inc.; Incyte Corporation; Janssen Pharmaceuticals; LEO Pharma; Lilly; Novartis Pharmaceuticals Corporation; Reddy Labs; Sun Pharmaceutical Industries, Ltd.; Xbiotech; UCB Pharma, Inc.; Valeant Pharmaceuticals International
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte Corporation; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation ; Xbiotech; UCB Pharma, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Celgene Corporation; Janssen Pharmaceuticals; Lilly; Pfizer Inc.; Novartis Pharmaceuticals Corporation
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Celgene Corporation; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation
Has disclosed no relevant financial relationships
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Janssen Pharmaceuticals; Roche; UCB Pharma, Inc.